E Fund Management Co., Ltd. Akero Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$17.76 - $31.18 $182,448 - $320,312	-10,273 Reduced 42.5%	13,899 $351,000
Q4 2023 Feb 06, 2024	BUY	$11.38 - $50.33 $167,786 - $742,065	14,744 Added 156.39%	24,172 $564,000
Q3 2023 Nov 13, 2023	BUY	$41.19 - $52.25 $37,812 - $47,965	918 Added 10.79%	9,428 $477,000
Q2 2023 Aug 11, 2023	SELL	$36.89 - $56.88 $30,618 - $47,210	-830 Reduced 8.89%	8,510 $397,000
Q1 2023 May 11, 2023	SELL	$37.27 - $50.24 $9,839 - $13,263	-264 Reduced 2.75%	9,340 $357,000
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $321,157 - $526,299	9,604 New	9,604 $526,000
Q1 2021 May 12, 2021	BUY	$24.04 - $34.19 $46,709 - $66,431	1,943 New	1,943 $56,000

170

72.7M

178K

164K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.38B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.